Hormonelle Kontrazeption und das Risiko für thromboembolische Erkrankungen

Auch wenn venöse Thromboembolien (VTE) bei jungen Menschen insgesamt seltener sind als bei älteren, erkranken und versterben in Deutschland nach wie vor deutlich mehr junge Frauen als junge Männer an VTE. Wesentliche Ursache hierfür ist die Anwendung kombinierter hormonaler Kontrazeptiva (KHK), also durch Präparate mit einem Östrogen + einem synthetischen Gestagen. Der Artikel fasst die Thromboserisiken der verschiedenen oralen und nichtoralen Kontrazeptiva zusammen insbesondere im Hinblick auf neuere KHK und die aktuelle gültige Leitlinie „Hormonelle Empfängnisverhütung“.

Abstract

Even though venous thromboembolism (VTE) is generally less common in young people than in older people, significantly more young women still get VTE and die from pulmonary embolism than young men in Germany. The main reason for this is the use of combined hormonal contraceptives (CHC), i.e. preparations containing an oestrogen + a synthetic progestogen. The article summarizes the thrombotic risks of the various oral and non-oral contraceptives, particularly with regard to newer combinded hormonal contracetpives and the current valid German guideline “Hormonal contraception”.

Schlüsselwörter

kombiniertes Kontrazeptivum - Schwangerschaft - Gestagen - Thrombophilie - venöse Thromboembolie

Keywords

pregnancy - thrombophilia - venous thromboembolism - progestin - combined contraceptive

Publication History

Received: 24 March 2025

Accepted after revision: 24 April 2025

Article published online:
15 July 2025

• Literatur

• 1 Linnemann BWB, Doenst T, Erbel C. et al. Diagnostik und Therapie der tiefen Venenthrombose und Lungenembolie – AWMF-S2k-Leitlinie. Stand: 11.01.2023. 2023.
• 2 Heinemann LA, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. Contraception 2007; 75 (05) 328-336
• 3 Linnemann B, Bauersachs R, Rott H. et al. Diagnosis of pregnancy-associated venous thromboembolism – position paper of the Working Group in Women's Health of the Society of Thrombosis and Haemostasis (GTH). VASA Zeitschrift fur Gefasskrankheiten 2016; 45 (02) 87-101
• 4 Sultan AA, West J, Tata LJ. et al. Risk of first venous thromboembolism in and around pregnancy: a population-based cohort study. British journal of haematology 2012; 156 (03) 366-373
• 5 Santosa F, Moysidis T, Moerchel C. et al. Pulmonary embolism in young people. Trends in Germany from 2005 to 2011. Hamostaseologie 2014; 34 (01) 88-92
• 6 Wiegratz I, Thaler CJ. Hormonal contraception--what kind, when, and for whom?. Dtsch Arztebl Int 2011; 108 (28) 495-505; quiz 6
• 7 Lidegaard O, Nielsen LH, Skovlund CW. et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9. BMJ (Clinical research ed) 2011; 343: d6423
• 8 Westhoff CL, Eisenberger A, Tang R. et al. Clotting factor changes during the first cycle of oral contraceptive use. Contraception 2016; 93 (01) 70-76
• 9 Stocco B, Fumagalli HF, Franceschini SA. et al. Comparative study of the effects of combined oral contraceptives in hemostatic variables: an observational preliminary study. Medicine 2015; 94 (04) e385
• 10 Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003; 89 (03) 493-498
• 11 Robinson GE, Burren T, Mackie IJ. et al. Changes in haemostasis after stopping the combined contraceptive pill: implications for major surgery. BMJ (Clinical research ed) 1991; 302 (6771) 269-71
• 12 Eischer L, Eichinger S, Kyrle PA. The risk of recurrence in women with venous thromboembolism while using estrogens: a prospective cohort study. Journal of thrombosis and haemostasis : JTH 2014; 12 (05) 635-640
• 13 Christiansen SC, Lijfering WM, Helmerhorst FM. et al. Sex difference in risk of recurrent venous thrombosis and the risk profile for a second event. Journal of thrombosis and haemostasis : JTH 2010; 8 (10) 2159-2168
• 14 Verlaan JPL, Stegeman BH, Timp JF. et al. Hormonal contraceptive use after a first venous thrombotic event and the risk of recurrence in premenopausal women. Journal of thrombosis and haemostasis : JTH 2024; 22 (08) 2195-2202
• 15 de Bastos M, Stegeman BH, Rosendaal FR. et al. Combined oral contraceptives: venous thrombosis. The Cochrane database of systematic reviews 2014; (03) Cd010813
• 16 Rote Hand Brief „kombinierte hormonale Kontrazeptiva. 30.09.2019.
• 17 Ziller M, Ziller V, Haas G. et al. Risk of venous thrombosis in users of hormonal contraceptives in German gynaecological practices: a patient database analysis. Archives of gynecology and obstetrics 2014; 289 (02) 413-419
• 18 van Vliet HA, Bertina RM. et al. Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. Journal of thrombosis and haemostasis : JTH 2008; 6 (02) 346-351
• 19 Klipping C, Duijkers I, Parke S. et al. Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. Drugs in R&D 2011; 11 (02) 159-170
• 20 Gaussem P, Alhenc-Gelas M, Thomas JL. et al. Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17beta-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study. Thromb Haemost 2011; 105 (03) 560-567
• 21 Dinger J, Do Minh T, Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception 2016; 94 (04) 328-339
• 22 Fruzzetti F, Cagnacci A. Venous thrombosis and hormonal contraception: what's new with estradiol-based hormonal contraceptives?. Open Access J Contracept 2018; 9: 75-79
• 23 Kluft C, Zimmerman Y. et al. Reduced hemostatic effects with drospirenone-based oral contraceptives containing estetrol vs. ethinyl estradiol. Contraception 2017; 95 (02) 140-147
• 24 Douxfils J, Klipping C, Duijkers I. et al. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters. Contraception 2020; 102 (06) 396-402
• 25 Creinin MD, Westhoff CL, Bouchard C. et al. Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results. Contraception 2021; 104 (03) 222-228
• 26 Lidegaard O, Nielsen LH, Skovlund CW. et al. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001–10. BMJ (Clinical research ed) 2012; 344: e2990
• 27 Dore DD, Norman H, Loughlin J. et al. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users. Contraception 2010; 81 (05) 408-413
• 28 Tricotel A, Collin C, Zureik M. Impact of the sharp changes in the use of contraception in 2013 on the risk of pulmonary embolism in France. Journal of thrombosis and haemostasis : JTH 2015; 13 (09) 1576-1580
• 29 van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arteriosclerosis, thrombosis, and vascular biology 2010; 30 (11) 2297-3000
• 30 WHO Guidelines Approved by the Guidelines Review Committee. In: th, editor. Medical Eligibility Criteria for Contraceptive Use: A WHO Family Planning Cornerstone. Geneva: World Health Organization World Health Organization.; 2010.
• 31 Palacios S, Colli E, Regidor PA. Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill. Acta Obstet Gynecol Scand 2019; 98 (12) 1549-1557
• 32 Tepper NK, Whiteman MK, Marchbanks PA. et al. Progestin-only contraception and thromboembolism: A systematic review. Contraception 2016; 94 (06) 678-700
• 33 van Vlijmen EF, Wiewel-Verschueren S, Monster TB. et al. Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis. Journal of thrombosis and haemostasis : JTH 2016; 14 (07) 1393-1403
• 34 Bergendal A, Persson I, Odeberg J. et al. Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes. Obstetrics and gynecology 2014; 124 (03) 600-609
• 35 Wu O, Robertson L, Langhorne P. et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost 2005; 94 (01) 17-25
• 36 Martinelli I, Lensing AW, Middeldorp S. et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood 2016; 127 (11) 1417-1425
• 37 van Hylckama Vlieg A, Rosendaal FR. Interaction between oral contraceptive use and coagulation factor levels in deep venous thrombosis. Journal of thrombosis and haemostasis : JTH 2003; 1 (10) 2186-2190
• 38 Hugon-Rodin J, Horellou MH, Conard J. et al. Type of Combined Contraceptives, Factor V Leiden Mutation and Risk of Venous Thromboembolism. Thromb Haemost 2018; 118 (05) 922-928
• 39 Franik S, Bauersachs R, Beyer-Westendorf J. et al. Hormonal Contraception. Guideline of the DGGG, OEGGG and SGGG (S3 Level, AWMF Registry Number 015/015, January 2020). Geburtshilfe Frauenheilkd 2021; 81 (02) 152-182
• 40 BfArM. Rote Hand Brief zu kombinierten Kontrazeptiva. 2014.
• 41 Beyer-Westendorf J, Michalski F, Tittl L. et al. Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series. The Lancet Haematology 2016; 3 (10) e480-e488